Gonadotropin Hormone News and Research

RSS

Gonadotropins are protein hormones secreted by gonadotrope cells of the pituitary gland of vertebrates.

Results from Tulip PETAL Study of elagolix announced by Neurocrine Biosciences

Neurocrine Biosciences, Inc. today announced top-line efficacy and safety results from the Tulip PETAL Study (703 Study), its fifth Phase 2 clinical trial using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

10 Dec 2009

New article in Women's Health journal emphasizes the importance of early pregnancy detection

A new article published in the peer-reviewed journal Women's Health emphasizes the importance of early pregnancy detection. Using research conducted on behalf of Church & Dwight Co. Inc., the makers of First Response, the article reviews data that shows not all at-home pregnancy tests are created equal -First Response brand pregnancy tests are more sensitive and able to detect key variants of the pregnancy hormone better than other at home pregnancy tests.

9 Dec 2009

Results from Phase III pivotal study of FIRMAGON presented

Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurrence rate in a Phase III pivotal study of FIRMAGON® (monthly degarelix for injection) or monthly leuprolide in prostate cancer patients during the first year of treatment.

4 Dec 2009

Alpha-fetoprotein, a well-tolerated agent for treatment and prevention of breast cancer

Researchers have found that hormones produced during pregnancy induce a protein that directly inhibits the growth of breast cancer. This protein, alpha-fetoprotein (AFP), may serve as a viable, well-tolerated agent for the treatment and prevention of breast cancer, according to findings published in Cancer Prevention Research, a journal of the American Association for Cancer Research.

25 Nov 2009

Genetic sonogram improves accuracy of noninvasive prenatal screening and detection of Down syndrome

The addition of a "genetic sonogram" maximizes the accuracy of non-invasive testing for Down syndrome, said a Baylor College of Medicine researcher who was lead author of a landmark study in the current issue of Obstetrics and Gynecology.

21 Nov 2009

EMEA's CHMP recommends approval of Merck's ELONVA

Merck & Co., Inc. today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has recommended approval of ELONVA® (corifollitropin alfa injection) as a treatment in controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART) program.

20 Nov 2009

Gene therapy may hold promise for cryptorchid individuals risking infertility

EGR4 is a master gene responsible for fertility in cryptorchidism. Is gene therapy going to replace surgery?

18 Nov 2009

Ipsen receives marketing authorization in France for its 6-month sustained-release formulation of Decapeptyl

Ipsen, an innovation-driven global specialty pharmaceutical Group announces that the French regulatory authorities (Agence Française de Sécurité Sanitaire des Produits de Santé, AFSSAPS) have today granted the marketing authorization to the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) for the treatment of locally advanced and metastatic prostate cancer.

13 Nov 2009

Positive results from Celldex Therapeutics' Phase 1 studies of CDX-1307 cancer vaccine candidate

Celldex Therapeutics, Inc. today announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.

29 Oct 2009

Interim study analysis comparing MENOPUR with rFSH in GnRH Antagonist IVF cycles

Ferring Pharmaceuticals presented an interim study analysis indicating that MENOPUR® (menotropins for injection, USP) is effective in in vitro fertilization (IVF) cycles using a gonadotropin-releasing hormone (GnRH) antagonist. The results were presented in a poster at the 65th Annual Meeting of the American Society for Reproductive Medicine (ASRM) in Atlanta, October 17-21, 2009.

21 Oct 2009

Co-promotion agreement to promote Prosed DS to urologists and retail pharmacists

Timm Medical Technologies, Inc., a specialist Urology company, announced today its exclusive co-promotion agreement with Ferring Pharmaceuticals Inc., a Swiss-based biopharmaceutical company, for Prosed® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate) in the United States.

15 Oct 2009

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl®1 (triptorelin embonate2 22.5 mg) successfully completed its European decentralised registration procedure involving nine countries: Germany (reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain and The Netherlands.

13 Oct 2009

Hormone therapy for treating prostate cancer is linked to heart problems

Berlin, Germany: New research has found that hormone therapy used to treat men with advanced prostate cancer is associated with an increased chance of developing various heart problems. Some choices of therapy appear, however, to be less risky than others.

22 Sep 2009

Implantable device offers continuous cancer monitoring

Surgical removal of a tissue sample is now the standard for diagnosing cancer. Such procedures, known as biopsies, are accurate but offer only a snapshot of the tumor at a single moment in time.

21 Jul 2009

New treatments for infertility could be in the pipeline

Scientists at the University of Otago have found in their research into the brain circuits which control human fertility, that instead of the usual synapses, fertility is controlled by a thousand or so special neurons, which are linked by long, branch-like dendrites and they believe their discovery could lead to the development of new treatments for infertility.

23 Jun 2009

Low dose bisphenol-A exposure shows significant reproductive health effects in rats

New research from North Carolina State University and the National Institute of Environmental Health Sciences (NIEHS) shows significant reproductive health effects in rats that have been exposed to bisphenol-A (BPA) at levels equivalent to or below the dose that has been thought not to produce any adverse effects.

17 Jun 2009

New findings on how stress causes sexual dysfunction and infertility

University of California, Berkeley, researchers have found what they think is a critical and, until now, missing piece of the puzzle about how stress causes sexual dysfunction and infertility.

16 Jun 2009

New device could track tumor's growth

Surgical removal of a tissue sample is now the standard for diagnosing cancer. Such procedures, known as biopsies, are accurate but only offer a snapshot of the tumor at a single moment in time.

13 May 2009

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.

27 Apr 2009

Pregnancy hormone hCG protects against breast cancer even in short-term treatments

One of the most effective ways to prevent breast cancer is through a full-term pregnancy at an early age.

21 Apr 2009